摘要
目的:针对老年支气管哮喘患者采用通肺平喘汤联合布地奈德治疗的疗效和安全性分析。方法:收集2014年6月-2016年6月的支气管哮喘患者,随机分为对照组和观察组各60例,对照组采用布地奈德治疗,观察组采用通肺平喘汤联合布地奈德治疗。对比两组患者的临床疗效,治疗前后的Th17、Treg水平和不良反应发生率。结果:观察组临床疗效较对照组明显高(P<0.05),对比差异具有统计学意义;治疗前两组患者的Th17、Treg水平对比无显著差异(P>0.05),治疗后,两组患者的Th17、Treg水平较治疗前出现改善(P<0.05),观察组改善较对照组明显(P<0.05);对照组不良反应发生率为5.00%,观察组不良反应发生率为3.33%,两组患者的不良反应发生率对比,差异无统计学意义(P>0.05)。结论:采用通肺平喘汤联合布地奈德治疗老年支气管哮喘患者的临床疗效较好,对Th17、Treg水平改善较明显,临床运用安全性较高。
Objective： To evaluate the safety and efficacy of the Tongfei Pingchuan decoction（ 通肺平喘汤） with budesonide on bronchial asthma in the elderly. Methods： Patients with bronchial asthma from June 2014 to June 2016 were randomly divided into the control group and observation group. The control group was treated with budesonide, and the observation group was treated with the Tongfei Pingchuan decoction more. Results： The clinical efficacy in the observation group was significantly higher than the control group（P〈 0.05）. After treatment, the level of Th17 and Treg were improved in two groups（P〈 0.05）. The improvement in the observation group was significantly higher than that in the control group（P〈 0.05）. The incidence of adverse reactions in the control group was 5.00%, and 3.33% in the observation group（P〉 0.05）. Conclusion： The Tongfei Pingchuan decoction and budesonide on bronchial asthma in senile patients was effective, by improving Th17 and Treg levels, with higher safety.
出处
《中医临床研究》
2018年第14期130-131,共2页
Clinical Journal Of Chinese Medicine
关键词
支气管哮喘
通肺平喘汤
布地奈德
Bronchial asthma
The Tongfei Pingchuan decoction
Budesonide
